These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 4000333)

  • 1. Plasma antithrombin III concentration in patients on regular haemodialysis treatment.
    Jørgensen M; Eriksen HO; Tranebjaerg L
    Nephron; 1985; 40(1):22-4. PubMed ID: 4000333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antithrombin III and heparinemia in patients on hemodialysis].
    Nagami AE; Sesin AM; Nattero GN
    Rev Fac Cien Med Univ Nac Cordoba; 1988; 46(1):23-6. PubMed ID: 3273332
    [No Abstract]   [Full Text] [Related]  

  • 3. Choice of anticoagulant in a congenital antithrombin III (AT III)-deficient patient with chronic renal failure undergoing regular haemodialysis.
    Matsuo T; Yamada T; Yamanashi T; Kodama K
    Clin Lab Haematol; 1989; 11(3):213-9. PubMed ID: 2686903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antithrombin III in chronic renal insufficiency].
    Bekić-Kaluza S; Macanović M
    Med Arh; 1991; 45(1-2):3-8. PubMed ID: 1366314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombin III and heparin cofactor II in patients with chronic renal failure undergoing regular hemodialysis.
    Toulon P; Jacquot C; Capron L; Frydman MO; Vignon D; Aiach M
    Thromb Haemost; 1987 Jun; 57(3):263-8. PubMed ID: 3660328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma hypercoagulability in haemodialysis patients: impact of dialysis and anticoagulation.
    Ambühl PM; Wüthrich RP; Korte W; Schmid L; Krapf R
    Nephrol Dial Transplant; 1997 Nov; 12(11):2355-64. PubMed ID: 9394323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombin-III and platelets in haemodialysis patients.
    Brandt P; Jespersen J; Sørensen LH
    Nephron; 1981; 28(1):1-3. PubMed ID: 7266723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombin III in uremia.
    Jørgensen KA; Stoffersen E
    Scand J Urol Nephrol; 1979; 13(3):299-303. PubMed ID: 531528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antithrombin III activity during hemodialysis].
    Rydzewski A; Soszka J; Myśliwiec M
    Pol Arch Med Wewn; 1983 Feb; 69(2):123-8. PubMed ID: 6889150
    [No Abstract]   [Full Text] [Related]  

  • 10. [Acute effects of sulodexide on the lipid profile and on antithrombin III in patients with chronic renal insufficiency in hemodialysis treatment].
    Averna MR; Citarella P; Picone F; Capodicasa G; Galione A; Rini G; Notarbartolo A
    Clin Ter; 1984 Jan; 108(2):111-4. PubMed ID: 6232045
    [No Abstract]   [Full Text] [Related]  

  • 11. [The resistance of activated partial thromboplastin time to heparin infusion during hemodialysis].
    Camici M; Sagripanti A; Barsotti G; Baicchi U; Evangelisti L; Morelli E; Giovannetti S
    Minerva Med; 1995 Sep; 86(9):353-5. PubMed ID: 7501225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of hemodialysis and peritoneal dialysis on antithrombin III and platelets.
    Woo KT; Wei SS; Lee EJ; Lau YK; Lim CH
    Nephron; 1985; 40(1):25-8. PubMed ID: 4000334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulant therapy in a congenital antithrombin III (ATIII)-deficient patient with chronic renal failure undergoing regular hemodialysis.
    Matsuo T; Yamada T; Matsuo M; Sakai R
    Biomater Artif Cells Immobilization Biotechnol; 1991; 19(1):185-91. PubMed ID: 1751668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombin III supplementation allowed haemodialysis without heparin after kidney transplantation.
    Nicastro MA; Plana JL; Heller MV; Dorado EG; Zucchini A; Molinas FC
    Nephrol Dial Transplant; 1993; 8(11):1281-2. PubMed ID: 8302472
    [No Abstract]   [Full Text] [Related]  

  • 15. Platelets and antithrombin III in uraemia: the acute effect of haemodialysis.
    Knudsen F; Dyerberg J
    Scand J Clin Lab Invest; 1985 Jun; 45(4):341-7. PubMed ID: 3160101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane.
    Lavaud S; Canivet E; Wuillai A; Maheut H; Randoux C; Bonnet JM; Renaux JL; Chanard J
    Nephrol Dial Transplant; 2003 Oct; 18(10):2097-104. PubMed ID: 13679486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antithrombin III substitution in dialysis-dependent renal insufficiency].
    Schrader J; Köstering H; Kramer P; Scheler F
    Dtsch Med Wochenschr; 1982 Dec; 107(48):1847-50. PubMed ID: 7140568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of argatroban as an anticoagulant for haemodialysis in patients with antithrombin III deficiency.
    Ota K; Akizawa T; Hirasawa Y; Agishi T; Matsui N
    Nephrol Dial Transplant; 2003 Aug; 18(8):1623-30. PubMed ID: 12897104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic properties of dermatan sulphate (MF 701) in haemodialysis for chronic renal failure.
    Ryan KE; Lane DA; Flynn A; Ireland H; Boisclair M; Shepperd J; Curtis JR
    Thromb Haemost; 1992 Nov; 68(5):563-9. PubMed ID: 1455403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lipaemic profile of patients subjected to long-term haemodialysis and acute changes associated with haemodialysis and the use of heparin (author's transl)].
    Koslík S; Takác M
    Sb Lek; 1981 Jul; 83(6-7):162-8. PubMed ID: 7268304
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.